DiaMedica Therapeutics’ $16.4 Million Initial Public Offering

Faegre Baker Daniels guided Craig-Hallum Capital Group as the sole managing underwriter on the offering

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) (TSX-V:DMA), a clinical stage biopharmaceutical company, priced its initial public offering in the United States of 4,100,000 of its common shares at a price to the public of $4.00 per share. All of the common shares are being offered by DiaMedica. The common shares are expected to begin trading December 7, 2018 on The Nasdaq Capital Market under the symbol “DMAC.” The offering is expected to close on December 11, 2018, subject to the satisfaction of customary closing conditions.

DiaMedica expects to use the net proceeds from the offering to fund clinical development of DiaMedica’s lead drug candidate, DM199, to conduct research activities and for working capital and general corporate purposes. Craig-Hallum Capital Group LLC is acting as the sole managing underwriter for the initial public offering.

Faegre Baker Daniels advised Craig-Hallum Capital Group with Jonathan Zimmerman (Picture), Ben Stacke, Steve Conley and Kareem Tawfic.

Involved fees earner: Steven Conley – Faegre Baker Daniels; Ben Stacke – Faegre Baker Daniels; Kareem Tawfic – Faegre Baker Daniels; Jonathan Zimmerman – Faegre Baker Daniels;

Law Firms: Faegre Baker Daniels;

Clients: Craig-Hallum Capital Group LLC;

Print Friendly, PDF & Email

Author: Ambrogio Visconti